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1. INTRODUCTION {#ags312300-sec-0005}
===============

Anastomotic leakage has long been a concern among gastrointestinal surgeons. Its occurrence not only causes postoperative morbidity and mortality, but also lengthens hospital stay and increases hospital costs.[1](#ags312300-bib-0001){ref-type="ref"}, [2](#ags312300-bib-0002){ref-type="ref"} Importantly, anastomotic leakage worsens oncological outcomes in patients with resectable and curable malignancies, leading to poorer disease‐free survival, overall survival, and functional outcome.[3](#ags312300-bib-0003){ref-type="ref"}, [4](#ags312300-bib-0004){ref-type="ref"}

Multiple factors contribute to anastomotic leakage, and its incidence varies depending on the location of the anastomosis. Esophageal anastomoses have the highest incidence of leakage, and gastric anastomoses the lowest incidence, whereas the incidence of colorectal anastomotic leakage differs among publications and anastomosis sites, ranging from 1% to 20%.[5](#ags312300-bib-0005){ref-type="ref"}

The early recovery after surgery protocol has been proposed to reduce postoperative stress. The protocol aims to promote postoperative recovery, reduce hospital stay and, most importantly, reduce postoperative complications, especially cardiovascular and pulmonary complications.[6](#ags312300-bib-0006){ref-type="ref"} Non‐steroidal anti‐inflammatory drugs (NSAIDs) play a major part in this protocol as a means of postoperative pain control. However, application of the early recovery after surgery protocol has been associated with an increased incidence of anastomotic leakage,[7](#ags312300-bib-0007){ref-type="ref"} and it has been suggested that NSAIDs may be a causative factor in impaired anastomotic healing.

Many potential mechanisms have been proposed to explain how postoperative NSAID use may cause anastomotic leakage. NSAIDs decreased protective prostaglandins, and inhibited mucosal cyclooxygenase (COX)‐1, intestinal epithelial cell migration, and mucosal restitution in animal models[8](#ags312300-bib-0008){ref-type="ref"} which, in turn, reduced anastomotic tensile strength and collagen deposition causing delayed anastomotic healing.[9](#ags312300-bib-0009){ref-type="ref"}, [10](#ags312300-bib-0010){ref-type="ref"}, [11](#ags312300-bib-0011){ref-type="ref"}

Previous reviews have examined the correlation between postoperative NSAID use and anastomotic leakage, but most have considered colorectal anastomoses only.[7](#ags312300-bib-0007){ref-type="ref"}, [12](#ags312300-bib-0012){ref-type="ref"} However, we suggest that the mechanisms shown in animal models may be applicable to all gastrointestinal anastomoses. Furthermore, it is also possible that selective COX‐2 inhibitors may be safer than non‐selective NSAIDs in terms of preventing anastomotic leakage based on the above‐mentioned mechanism.

The primary objective of this systematic review and meta‐analysis was to determine the effect of postoperative NSAID use on gastrointestinal anastomotic leakage, regardless of the site of anastomosis. The secondary objective was to compare the anastomotic leakage risk between non‐selective NSAIDs and selective COX‐2 inhibitors.

2. METHODS {#ags312300-sec-0006}
==========

2.1. Search strategy {#ags312300-sec-0007}
--------------------

We conducted a literature search of the Medline, PubMed, Cochrane Library, <http://clinicaltrial.gov>, and Web of Science databases up to August 2018. The search was limited to English language and human studies. The search terms used were "Anastomosis or anastomotic leakage" AND "NSAIDs" \[MesH term\]. Additional articles were retrieved by manually searching the reference lists of the included studies and other reviews.

2.2. Selection criteria {#ags312300-sec-0008}
-----------------------

Studies were included if they met the following criteria: (i) study with anastomosis of the gastrointestinal tract; (ii) study compared postoperative NSAID use with non‐use; and (iii) investigations reported anastomotic leakage. Case reports or reports with incomplete data were excluded.

2.3. Data extraction {#ags312300-sec-0009}
--------------------

The studies were independently and critically assessed by two authors using a standard protocol and discrepancies were resolved by consensus. Extracted data included study design, number of institutes, definition of anastomotic leakage, operative diagnosis, location of anastomosis, urgency of surgery, type of NSAIDs, sample size, and numbers of anastomotic leakage per group.

2.4. Quality assessment {#ags312300-sec-0010}
-----------------------

Qualities of the included studies were assessed using the Jadad score[13](#ags312300-bib-0013){ref-type="ref"} and the Newcastle‐Ottawa scale (NOS)[14](#ags312300-bib-0014){ref-type="ref"} for randomized controlled trials (RCT) and observational studies, respectively. Studies were considered to be high quality if they had a Jadad score ≥3 or NOS ≥7.

2.5. Data synthesis and meta‐analysis {#ags312300-sec-0011}
-------------------------------------

Meta‐analysis was done by computing the OR from the original data using the Cochrane‐Mantel‐Haenszel method, with 95% CI. *P* ≤ .05 was considered significant in all analyses. Data analysis was carried out using Review Manager (RevMan) v5.3 software (Cochrane Collaboration) and a random‐effect model was used for graphical presentation. Statistical heterogeneity was quantified using I^2^ statistics and Cochrane Q tests. I^2^ values \>50% indicated heterogeneity.[15](#ags312300-bib-0015){ref-type="ref"} In the presence of heterogeneity, we conducted subgroup and meta‐regression analyses to determine if the inter‐study variation could be explained by certain co‐variates, including type of study, NSAID class, NSAID administration, urgency of surgery, location of anastomosis, and operative diagnosis. Sensitivity analyses were done to assess the impact of individual potential confounding variables. Publication bias was assessed visually by funnel plot, and asymmetry was assessed formally by rank correlation test (Begg's test).[16](#ags312300-bib-0016){ref-type="ref"} Publication bias was analyzed using WINPEPI software.[17](#ags312300-bib-0017){ref-type="ref"}

3. RESULTS {#ags312300-sec-0012}
==========

3.1. Study selection {#ags312300-sec-0013}
--------------------

The initial systematic search identified 430 studies and an additional search for reviews identified a further five studies. After adjusting for duplicates and critical assessment, a total of six RCT[18](#ags312300-bib-0018){ref-type="ref"}, [19](#ags312300-bib-0019){ref-type="ref"}, [20](#ags312300-bib-0020){ref-type="ref"}, [21](#ags312300-bib-0021){ref-type="ref"}, [22](#ags312300-bib-0022){ref-type="ref"}, [23](#ags312300-bib-0023){ref-type="ref"} and 18 observational studies[24](#ags312300-bib-0024){ref-type="ref"}, [25](#ags312300-bib-0025){ref-type="ref"}, [26](#ags312300-bib-0026){ref-type="ref"}, [27](#ags312300-bib-0027){ref-type="ref"}, [28](#ags312300-bib-0028){ref-type="ref"}, [29](#ags312300-bib-0029){ref-type="ref"}, [30](#ags312300-bib-0030){ref-type="ref"}, [31](#ags312300-bib-0031){ref-type="ref"}, [32](#ags312300-bib-0032){ref-type="ref"}, [33](#ags312300-bib-0033){ref-type="ref"}, [34](#ags312300-bib-0034){ref-type="ref"}, [35](#ags312300-bib-0035){ref-type="ref"}, [36](#ags312300-bib-0036){ref-type="ref"}, [37](#ags312300-bib-0037){ref-type="ref"}, [38](#ags312300-bib-0038){ref-type="ref"}, [39](#ags312300-bib-0039){ref-type="ref"}, [40](#ags312300-bib-0040){ref-type="ref"}, [41](#ags312300-bib-0041){ref-type="ref"} were included in the meta‐analysis. The PRISMA flow diagram of the detailed literature search and selection process is shown in Figure [1](#ags312300-fig-0001){ref-type="fig"}. Of 27 full‐text article reviews, three were excluded from the quantitative analysis because we could not extract the original data from two, and the other study compared multimodal interventions in which NSAIDs were also distributed to the control group.

![PRISMA flow shows study selection process. NSAIDs, non‐steroidal anti‐inflammatory drugs; RCT, randomized controlled trial](AGS3-4-64-g001){#ags312300-fig-0001}

3.2. Characteristics of included studies {#ags312300-sec-0014}
----------------------------------------

Six RCT and 18 observational studies were included in this meta‐analysis. Sample sizes varied from 40 to 220 for the RCT and from 75 to 13 082 for the observational studies. Most studies included the anastomotic location as colorectal anastomoses (four RCT,[18](#ags312300-bib-0018){ref-type="ref"}, [19](#ags312300-bib-0019){ref-type="ref"}, [21](#ags312300-bib-0021){ref-type="ref"}, [22](#ags312300-bib-0022){ref-type="ref"} 13 observational studies[24](#ags312300-bib-0024){ref-type="ref"}, [25](#ags312300-bib-0025){ref-type="ref"}, [26](#ags312300-bib-0026){ref-type="ref"}, [27](#ags312300-bib-0027){ref-type="ref"}, [28](#ags312300-bib-0028){ref-type="ref"}, [29](#ags312300-bib-0029){ref-type="ref"}, [31](#ags312300-bib-0031){ref-type="ref"}, [32](#ags312300-bib-0032){ref-type="ref"}, [34](#ags312300-bib-0034){ref-type="ref"}, [35](#ags312300-bib-0035){ref-type="ref"}, [36](#ags312300-bib-0036){ref-type="ref"}, [38](#ags312300-bib-0038){ref-type="ref"}, [40](#ags312300-bib-0040){ref-type="ref"}), a diagnosis of malignancy (three RCT,[19](#ags312300-bib-0019){ref-type="ref"}, [20](#ags312300-bib-0020){ref-type="ref"}, [21](#ags312300-bib-0021){ref-type="ref"} six observational studies[24](#ags312300-bib-0024){ref-type="ref"}, [28](#ags312300-bib-0028){ref-type="ref"}, [36](#ags312300-bib-0036){ref-type="ref"}, [38](#ags312300-bib-0038){ref-type="ref"}, [40](#ags312300-bib-0040){ref-type="ref"}, [41](#ags312300-bib-0041){ref-type="ref"}), and surgery carried out as an elective procedure (all RCT, 12 observational studies[24](#ags312300-bib-0024){ref-type="ref"}, [25](#ags312300-bib-0025){ref-type="ref"}, [26](#ags312300-bib-0026){ref-type="ref"}, [28](#ags312300-bib-0028){ref-type="ref"}, [29](#ags312300-bib-0029){ref-type="ref"}, [31](#ags312300-bib-0031){ref-type="ref"}, [32](#ags312300-bib-0032){ref-type="ref"}, [35](#ags312300-bib-0035){ref-type="ref"}, [36](#ags312300-bib-0036){ref-type="ref"}, [38](#ags312300-bib-0038){ref-type="ref"}, [40](#ags312300-bib-0040){ref-type="ref"}, [41](#ags312300-bib-0041){ref-type="ref"}). Most studies reported the classes of NSAIDs used, except for five observational studies, from some of which we were able to extract the original data. Data on non‐selective NSAIDs were extracted from 15 studies[18](#ags312300-bib-0018){ref-type="ref"}, [19](#ags312300-bib-0019){ref-type="ref"}, [21](#ags312300-bib-0021){ref-type="ref"}, [22](#ags312300-bib-0022){ref-type="ref"}, [23](#ags312300-bib-0023){ref-type="ref"}, [24](#ags312300-bib-0024){ref-type="ref"}, [26](#ags312300-bib-0026){ref-type="ref"}, [27](#ags312300-bib-0027){ref-type="ref"}, [28](#ags312300-bib-0028){ref-type="ref"}, [31](#ags312300-bib-0031){ref-type="ref"}, [36](#ags312300-bib-0036){ref-type="ref"}, [37](#ags312300-bib-0037){ref-type="ref"}, [38](#ags312300-bib-0038){ref-type="ref"}, [40](#ags312300-bib-0040){ref-type="ref"}, [41](#ags312300-bib-0041){ref-type="ref"} and on selective COX‐2 inhibitors from eight studies.[20](#ags312300-bib-0020){ref-type="ref"}, [23](#ags312300-bib-0023){ref-type="ref"}, [25](#ags312300-bib-0025){ref-type="ref"}, [27](#ags312300-bib-0027){ref-type="ref"}, [29](#ags312300-bib-0029){ref-type="ref"}, [35](#ags312300-bib-0035){ref-type="ref"}, [38](#ags312300-bib-0038){ref-type="ref"}, [40](#ags312300-bib-0040){ref-type="ref"} Quality assessment showed that all the RCT and all but two of the observational studies were high quality,[24](#ags312300-bib-0024){ref-type="ref"}, [35](#ags312300-bib-0035){ref-type="ref"} with the two observational studies considered low quality. Characteristics of the included studies are outlined in Table [1](#ags312300-tbl-0001){ref-type="table"}.

###### 

Characteristics of included studies to determine the correlation between the use of NSAIDs and anastomotic leakage

  Author, year                                                 Study design                                          Country, Institute          Recruitment period   Definition of AL                                                                          Diagnosis                         Location of anastomosis                          Urgency of surgery       N       NSAIDs administration                                                                           Quality assessment[a](#ags312300-note-0002){ref-type="fn"}
  ------------------------------------------------------------ ----------------------------------------------------- --------------------------- -------------------- ----------------------------------------------------------------------------------------- --------------------------------- ------------------------------------------------ ------------------------ ------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------
  Chen,[18](#ags312300-bib-0018){ref-type="ref"} 2005          RCT, Double‐blind                                     Taiwan, single              2003                 NR                                                                                        Mixed                             Colorectal                                       Elective                 74      PCA: ketolorac 1.2 g/mL + morphine 1 mg/mL 2 mL bolus and 10 min lockout until pain score \<3   5
  Schlachta,[19](#ags312300-bib-0019){ref-type="ref"} 2007     RCT, Double‐blind                                     Canada, single              2002‐2005            NR                                                                                        Mixed (Cancer 50%)                Colorectal                                       Elective                 44      Ketolorac 30 mg IV every 6 h for 2 d after operation                                            3
  Sim,[20](#ags312300-bib-0020){ref-type="ref"} 2007           RCT, Double‐blind                                     Singapore, single           2002‐2004            NR                                                                                        Mixed (Cancer 94.9%)              Mixed (Colorectal 94.9%)                         Elective                 79      Valdecoxib 40 mg orally once pre‐operation and once daily for 5 d after operation               2
  Xu,[21](#ags312300-bib-0021){ref-type="ref"} 2008            RCT, Double‐blind                                     China, single               2006‐2007            NR                                                                                        Cancer                            Colorectal                                       Elective                 40      Flurbiprofen 1 mg/kg IV 30 min before and 6 h after skin incision                               5
  Chen,[22](#ags312300-bib-0022){ref-type="ref"} 2009          RCT, Double‐blind                                     Taiwan, single              2006‐2007            NR                                                                                        Mixed                             Colorectal                                       Elective                 102     PCA: ketolorac 1.2 g/mL + morphine 1 mg/mL 2 mL bolus and 10 min lockout until pain score \<3   4
  Wattchow,[23](#ags312300-bib-0023){ref-type="ref"} 2009      RCT, Double‐blind                                     Australia, 2 institutes     2003‐2006            NR                                                                                        Mixed                             Mixed (Colorectal 99%, Small intestine 1%)       Elective                 220     Celecoxib 100 mg or Diclofenac 50 mg orally twice daily for 7 d or until discharge              4
  Rosenberg,[24](#ags312300-bib-0024){ref-type="ref"} 2007     Retrospective cohort                                  Denmark, Single             2004‐2006            NR                                                                                        Cancer                            Colorectal                                       Elective                 310     Diclofenac 75 mg twice daily, Not reported duration                                             5
  Klein,[26](#ags312300-bib-0026){ref-type="ref"} 2009         Retrospective case‐control                            Denmark, Single             2004‐2007            Leak requiring reoperation                                                                Mixed (Cancer 96%)                Colorectal                                       Elective                 75      Diclofenac 150 mg/d, Not reported duration                                                      7
  Holte,[25](#ags312300-bib-0025){ref-type="ref"} 2009         Retrospective cohort                                  Denmark, Single             1997‐2006            Radiologic finding or intra‐operative finding or clinical finding                         NR                                Colon                                            Elective                 502     Ibuprofen 600 mg every 8 h or Celecoxib 200 mg every 12 h at POD 2‐8                            7
  Gorissen,[27](#ags312300-bib-0027){ref-type="ref"} 2012      Retrospective cohort                                  Netherlands, 2 institutes   2008‐2010            Radiologic finding or intra‐operative finding or clinical finding                         Mixed (Cancer 72%)                Colorectal                                       Mixed (Elective 86.4%)   795     NSAIDs use within POD 5                                                                         8
  Klein,[28](#ags312300-bib-0028){ref-type="ref"} 2012         Retrospective cohort                                  Denmark, 6 institutes       2006‐2009            Leak requring reoperation                                                                 Cancer                            Colorectal                                       Elective                 2752    NSAIDs use at least 2 d within POD 7                                                            9
  Zittel,[29](#ags312300-bib-0029){ref-type="ref"} 2013        Retrospective cohort                                  Sweden, single              2008‐2009            NR                                                                                        Mixed (Cancer 57.6%)              Colorectal                                       Elective                 205     Etoricoxib 120 mg once daily, Not reported duration                                             8
  Subendran,[32](#ags312300-bib-0032){ref-type="ref"} 2014     Retrospective case‐control                            Canada, single              2001‐2012            Radiologic finding or intra‐operative finding                                             Mixed (IBD 65.6%, cancer 34.4%)   Colorectal                                       Elective                 262     NSAIDs use within POD 5                                                                         8
  Saleh,[31](#ags312300-bib-0031){ref-type="ref"} 2014         Retrospective cohort                                  Canada, single              2004‐2011            Document at reoperation or Radiological finding                                           Mixed (Cancer 65.5%)              Colorectal                                       Elective                 731     NSAIDs use within POD 5                                                                         8
  STARSurg UK,[30](#ags312300-bib-0030){ref-type="ref"} 2014   Prospective cohort                                    UK, multi‐institutes        2013                 Radiologic finding or intra‐operative finding or clinical finding                         Mixed (Cancer 62.1%)              Mixed (Colorectal 75.9%)                         Mixed (Elective 72.1%)   1503    NSAIDs use within POD 2                                                                         8
  Paulsir,[34](#ags312300-bib-0034){ref-type="ref"} 2015       Retrospective cohort                                  USA, multi‐institutes       2012‐2014            Leaks requiring antibiotic or intervention or reoperation                                 NR                                Colorectal                                       Mixed (Elective 78.6%)   4360    NSAIDs use within POD 1                                                                         9
  Hakkarainen,[33](#ags312300-bib-0033){ref-type="ref"} 2015   Retrospective cohort                                  USA, 47 institutes          2006‐2010            Leak requiring percutaneous drainage or reoperaion                                        NR                                Bariatic, Colorectal                             Mixed (Elective 87.6%)   13082   NSAIDs use within POD 1                                                                         9
  Raju,[35](#ags312300-bib-0035){ref-type="ref"} 2015          Retrospective cohort                                  Australia, 2 institutes     2008‐2014            Leak requiring percutaneous drainage or reoperaion                                        Mixed (Cancer 70.6%)              Colorectal                                       Elective                 267     Celecoxib 100 mg twice daily start at 2 h before operation to POD 7                             6
  Bakker,[36](#ags312300-bib-0036){ref-type="ref"} 2016        Retrospective cohort                                  Netherlands, single         2006‐2013            Leak requiring percutaneous drainage or reoperaion                                        Cancer                            Colorectal                                       Elective                 856     NSAIDs use at least 2 d until discharge                                                         8
  Rutegard,[38](#ags312300-bib-0038){ref-type="ref"} 2016      Retrospective cohort                                  Sweden, multi‐institutes    2007‐2012            Leak requiring percutaneous drainage or reoperaion                                        Cancer                            Rectum                                           Elective                 2605    NSAIDs use within POD 10                                                                        8
  Rushfeldt,[37](#ags312300-bib-0037){ref-type="ref"} 2016     Retrospective cohort with propensity score analysis   Norway, Single              2007‐2009            NR                                                                                        Mixed (Cancer 52.8%)              Mixed (Colorectal 73.4%)                         Mixed (Elective 88%)     428     NSAIDs use within POD 5                                                                         8
  Haddad,[39](#ags312300-bib-0039){ref-type="ref"} 2017        Retrospective cohort                                  USA, multi‐institutes       2013‐2015            NR                                                                                        Trauma                            Mixed (Small intestine 93.4%, Colorectal 6.6%)   Emergency                533     NSAIDs use 7 d prior to operation up to POD 14                                                  7
  Fjederholt,[41](#ags312300-bib-0041){ref-type="ref"} 2018    Retrospective cohort                                  Denmark, 2 institutes       2003‐2012            Radiologic finding or endoscopic finding                                                  Cancer                            Esophagojejunostomy                              Elective                 556     NSAIDs use within POD 7                                                                         9
  Hultberg,[40](#ags312300-bib-0040){ref-type="ref"} 2017      Retrospective cohort                                  Sweden, 15 institutes       2007‐2013            Radiologic finding or intra‐operative finding or clinical finding or Endoscopic finding   Cancer                            Rectal                                           Elective                 1495    NSAIDs use at least 2 d within POD 7                                                            9

Abbreviations: AL, anastomotic leakage; IBD, inflammatory bowel disease; NR, not reported; NSAIDs, non‐steroidal anti‐inflammatory drugs; PCA, patient controlled analgesia; POD, postoperative day; RCT, randomised controlled trial.

Quality assessment for RCT and observational studies using Jadad score and Newcastle‐Ottawa scale (NOS) for randomised controlled trials (RCTs) and observational studies, respectively.
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3.3. Association of NSAIDs with anastomotic leakage {#ags312300-sec-0015}
---------------------------------------------------

Overall anastomotic leakage rate in this study was 6.0% (1922/31 877). Patients who received NSAIDs postoperatively had a higher leakage rate (7.5%; 777/10 318) than those without NSAIDs (5.3%; 1145/21 558). Meta‐analysis showed a significantly higher rate of anastomotic leakage after postoperative NSAID use (pooled OR 1.73, 95% CI 1.31‐2.29, *P* \< .001), but with evidence of heterogeneity across the included studies (I^2^ = 80%, Cochrane Q test *P* \< .00001) (Figure [2](#ags312300-fig-0002){ref-type="fig"}). The funnel plot appeared relatively symmetrical, suggesting no publication bias, as confirmed by Begg's test (*P* = .444) (Figure [3](#ags312300-fig-0003){ref-type="fig"}). There was some discrepancy in the results between the study types: RCT showed a non‐significant difference in anastomotic leakage between the NSAID and placebo groups (pooled OR 1.91, 95%CI 0.69‐5.35, *P* = .67) without heterogeneity (I^2^ = 0%, Cochrane Q test *P* = .67), whereas observational studies found a significantly higher leakage rate after postoperative NSAID use (OR 1.72, 95%CI 1.28‐2.31, *P* \< .001) with evidence of heterogeneity (I^2^ = 84%, Cochrane Q test *P* \< .001) (Figure [2](#ags312300-fig-0002){ref-type="fig"}).

![Forrest plot of meta‐analysis between randomized controlled trials (RCT) and observational studies. NSAIDs, non‐steroidal anti‐inflammatory drugs](AGS3-4-64-g002){#ags312300-fig-0002}

![Funnel plot with pseudo 95% CI (random‐effect model). OR, odds ratio; SE, study effect](AGS3-4-64-g003){#ags312300-fig-0003}

3.4. Protocol‐based versus non‐systematic NSAIDs use {#ags312300-sec-0016}
----------------------------------------------------

To investigate the effect of NSAID dose on anastomotic leakage, we categorized NSAID use in the included studies into protocol‐based and non‐systematic use. In the protocol‐based group, NSAIDs were given according to the institutional protocol (11 studies; n = 1918), whereas in the non‐systematic group, NSAIDs were given at any given time during the postoperative period (13 studies; n = 30 140). Details of NSAID use are shown in Table [1](#ags312300-tbl-0001){ref-type="table"}. The protocol‐based group had a significantly higher anastomotic leakage rate compared with non‐users (pooled OR 4.67, 95% CI 2.84‐7.67, *P* \< .001) without evidence of heterogeneity (I^2^ = 5%, Cochrane Q test *P* = .40), whereas the non‐systematic group also had a significantly increased risk for anastomotic leakage compared with non‐users (pooled OR 1.38, 95% CI 1.06‐0.181, *P* = .02), but with evidence of heterogeneity (I^2^ = 82%, Cochrane Q test *P* \< .001). However, there was a statistically significant subgroup difference between the protocol‐based group and the non‐systematic group (*P* \< .001) (Figure [4](#ags312300-fig-0004){ref-type="fig"}).

![Forrest plot of meta‐analysis between protocol‐based non‐steroidal anti‐inflammatory drugs (NSAIDs) use and non‐systematic NSAIDs use](AGS3-4-64-g004){#ags312300-fig-0004}

3.5. Non‐selective NSAIDs versus selective COX‐2 inhibitors {#ags312300-sec-0017}
-----------------------------------------------------------

Among all the included studies, we extracted information on non‐selective NSAID use from 15 (n = 4110) and on selective COX‐2 inhibitor use from eight (n = 1063) studies. Subgroup analysis showed that patients who received postoperative non‐selective NSAIDs had a significantly higher rate of anastomotic leakage than patients who did not receive NSAIDs (pooled OR 1.80, 95% CI 1.12‐2.91, *P* = .02) with evidence of heterogeneity (I^2^ = 85%, Cochrane Q test *P* \< .00001). In contrast, the anastomotic leakage rate in patients taking selective COX‐2 inhibitors was not significantly higher than in those not taking NSAIDs (pooled OR = 1.67, 95% CI 0.90‐3.13, *P* = .11), with evidence of heterogeneity (I^2^ = 67%, Cochrane Q test *P* = .004). However, comparison between users of non‐selective and selective NSAIDs showed no significant subgroup difference (*P* = .85) (Figure [5](#ags312300-fig-0005){ref-type="fig"}).

![Forrest plot of meta‐analysis between non‐selective non‐steroidal anti‐inflammatory drugs (NSAIDs) and selective COX‐2 NSAIDs](AGS3-4-64-g005){#ags312300-fig-0005}

3.6. Colorectal anastomoses versus other gastrointestinal anastomoses {#ags312300-sec-0018}
---------------------------------------------------------------------

We carried out subgroup analyses between studies restricted to colorectal anastomoses (17 studies; n = 15 475) and studies with anastomoses not limited to colorectal (seven studies; n = 16 538). Studies with colorectal anastomoses had significantly increased anastomotic leakage rates when perioperative NSAIDs were used (pooled OR 1.80, 95% CI 1.22‐2.66, *P* = .003), with evidence of heterogeneity (I^2^ = 83%, Cochrane Q test *P* \< .00001). Studies of anastomoses of all sites also showed significantly higher rates of anastomotic leakage (pooled OR 1.61, 95% CI 1.25‐2.66, *P* = .02), with evidence of heterogeneity (I^2^ = 72%, Cochrane Q test *P* = .002). There were no subgroup differences between the two groups of studies (*P* = .85) (Figure [S1](#ags312300-sup-0001){ref-type="supplementary-material"}).

3.7. Meta‐regression and sensitivity analyses {#ags312300-sec-0019}
---------------------------------------------

Meta‐regression analysis stratified by location of anastomoses showed pooled OR for anastomotic leakage of 1.80 (95% CI 1.22‐2.66, I^2^ = 83%) for colorectal anastomoses and 1.70 (95% CI 1.09‐2.66, I^2^ = 72%) for studies that were not limited to colorectal anastomoses. Meta‐regression analysis showed no significant difference between various anastomotic sites (*P* = .85). Furthermore, separate stratified and meta‐regression analyses showed no significant differences in the OR of anastomotic leakage rates after postoperative NSAID use in relation to the type of study, NSAID class, urgency of surgery, or operative diagnosis (Table [2](#ags312300-tbl-0002){ref-type="table"}).

###### 

Stratified analysis and meta‐regression of included studies

                                  Studies   N        OR (95% CI)        *I* ^2^   Heterogeneity          
  ------------------------------- --------- -------- ------------------ --------- --------------- ------ ---------
  1\. Type of studies                                                                                    
  RCTS                            6         559      1.91 (0.69‐5.35)   0         0.06            0      .81
  Cohort studies                  18        31 317   1.68 (1.25‐2.24)   83                               
  2\. NSAIDs class                                                                                       
  Non selective                   15        10 424   1.80 (1.12‐2.91)   85        0.03            0      .85
  Selective COX‐2                 8         4404     1.67 (0.90‐3.13)   67                               
  3\. Urgency of surgery                                                                                 
  Elective                        18        11 175   2.08 (1.31‐3.29)   84        4.55            72     .03
  Not limit to elective surgery   6         20 701   1.23 (1.06‐1.42)   0                                
  4\. Location of anastamoses                                                                            
  Colorectal                      17        15 475   1.80 (1.22‐2.66)   83        0.20            0      .66
  Not limit to colorectal         7         16 401   1.58 (1.04‐2.42)   72                               
  5\. Diagnosis                                                                                          
  Cancer                          7         8614     1.88 (0.96‐3.69)   93        0.31            0      .58
  Not limit to cancer             17        23 262   1.54 (1.21‐1.96)   44                               
  6\. NSAIDs administration                                                                              
  Protocol based                  11        1918     4.67 (2.84‐7.67)   5         18.78           94.7   \<.0001
  Unsystematic                    13        29 958   1.34 (1.03‐1.75)   81                               

Abbreviations: CI, confidence interval; NSAIDs, non‐steroidal anti‐inflammatory drugs; OR, odds ratio; RCT, randomized controlled trial
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Sensitivity analyses were carried out to assess the impact of low‐quality studies (Table [1](#ags312300-tbl-0001){ref-type="table"}). Exclusion of the two low‐quality studies did not affect the significance of the results (pooled OR 1.61, 95% CI 1.22‐2.11, *P* \< .001).

4. DISCUSSION {#ags312300-sec-0020}
=============

Numerous mechanisms have shown how NSAIDs can damage human intestines, although some remain controversial. Non‐selective NSAIDs have been associated with enterocyte mitochondrial dysfunction leading to increased epithelial permeability, invasion of luminal bacteria, neutrophil infiltration, and free radical production.[42](#ags312300-bib-0042){ref-type="ref"}, [43](#ags312300-bib-0043){ref-type="ref"}, [44](#ags312300-bib-0044){ref-type="ref"} Inhibition of COX by NSAIDs also decreases protective prostaglandins.[45](#ags312300-bib-0045){ref-type="ref"} Non‐selective NSAIDs and their acidic compounds can cause topical mucosal injury.[9](#ags312300-bib-0009){ref-type="ref"} However, most COX in the intestinal mucosal layer are COX‐1, and selective COX‐2 inhibitors may thus be more tolerable in the normal gastrointestinal tract.

Selective COX‐2 inhibitors and non‐selective NSAIDs confound the anastomotic healing process. Submucosal collagen fibers provide a core structure that determines tensile strength, and both selective COX‐2 inhibitors and non‐selective NSAIDs adversely affected this structure in an animal model which, in turn, led to decreased tensile strength of the anastomoses and reduced bursting pressure.[46](#ags312300-bib-0046){ref-type="ref"}, [47](#ags312300-bib-0047){ref-type="ref"}, [48](#ags312300-bib-0048){ref-type="ref"} NSAIDs also inhibited epithelial cell migration and mucosal restitution by depolarization and decreased surface expression of potassium channels.[8](#ags312300-bib-0008){ref-type="ref"} However, unlike in normal tissue, enterocytes express high levels of COX‐2 during inflammation, which catalyzes prostaglandin E2, resulting in increased vascular endothelial growth factor expression and angiogenesis.[49](#ags312300-bib-0049){ref-type="ref"}

The above results and hypotheses shed doubt on the safety of postoperative NSAID use for analgesic control. Numerous previous meta‐analyses have shown significantly higher anastomotic leakage rates in patients given NSAIDs.[7](#ags312300-bib-0007){ref-type="ref"}, [12](#ags312300-bib-0012){ref-type="ref"}, [50](#ags312300-bib-0050){ref-type="ref"} The current systematic review and meta‐analysis confirmed the association between postoperative NSAID use and higher anastomotic leakage (pooled OR 1.73, 95% CI 1.31‐2.29, *P* \< .001). However, our analysis of RCT did not show a significant effect of postoperative NSAIDs on anastomotic leakage rate compared with placebo. This meta‐analysis included only six RCT. Furthermore, the primary outcome of all RCT were not anastomotic leakage; therefore, we extracted corresponding data from each RCT. Finally, the sample size from RCT was very small compared to observational studies (n = 559 vs 31 499), which makes it relatively reasonable to integrate both study designs in order to make a conclusion from current evidence. From the result of no significant subgroup difference between studies, RCT and all designs, we believe that the controversial result may be explainable by the small sample sizes of the RCT, thus limiting their statistical power, rather than by the absence of a relationship between NSAIDs use and anastomotic leakage.

Subgroup analysis showed that patients taking NSAIDs according to hospital protocol had significantly higher rates of anastomotic leakage than those not taking NSAIDs (pooled OR 4.67, 95% CI 2.84‐7.67, *P* \< .001), without evidence of heterogeneity (I^2^ = 5%, Cochrane Q test *P* = .40). Patients in the protocol‐based group were supposedly given NSAIDs in a regular way, with higher cumulative doses compared with the non‐systematic group. This suggests that the association between NSAID use and anastomotic leakage may be dose‐related, although further studies are needed to confirm this theory.

Subgroup analysis also showed that patients taking non‐selective NSAIDs had a significantly higher rate of anastomotic leakage than patients not taking NSAIDs (pooled OR 1.80, 95% CI 1.12‐2.91, *P* = .02). In contrast, selective COX‐2 inhibitors tended to increase the risk of anastomotic leakage, but the effect was not significant (pooled OR = 1.67, 95% CI 0.90‐3.13, *P* = .11). However, there was no significant subgroup difference between patients taking non‐selective and COX‐2‐selective NSAIDs. These results support the hypotheses that both classes of NSAIDs had adverse effects on anastomotic healing, leading to increased anastomotic leakage; however, non‐selective NSAIDs might cause greater damage then selective COX‐2 inhibitors by causing intestinal mucosal injury, at least in part.

In animal models, adverse effects of NSAIDs were found in both small intestine and colon resulting in increased anastomotic leakage rate.[8](#ags312300-bib-0008){ref-type="ref"}, [9](#ags312300-bib-0009){ref-type="ref"}, [11](#ags312300-bib-0011){ref-type="ref"}, [42](#ags312300-bib-0042){ref-type="ref"}, [44](#ags312300-bib-0044){ref-type="ref"} In human studies, consistent results were also reported regardless of anastomotic site; however, the majority were colorectal anastomoses. In our study, studies with colorectal anastomoses had significantly increased anastomotic leakage rates when perioperative NSAIDs were used (pooled OR 1.80, 95% CI 1.22‐2.66, *P* = .003). Consistently, studies of anastomoses of all sites also showed significantly higher rates of anastomotic leakage (pooled OR 1.61, 95% CI 1.25‐2.66, *P* = .02). There were no subgroup differences between the two groups of studies (*P* = .85). In fact, Fjederholt et al[41](#ags312300-bib-0041){ref-type="ref"} reported a strong association between NSAIDs use and the risk of anastomotic leakage (ketorolac; OR 6.05, 95% CI 2.71‐13.5) (other NSAIDs; OR 5.24, 95% CI 1.85‐14.8) after surgery for gastroesophageal junction only. Two other studies[33](#ags312300-bib-0033){ref-type="ref"}, [39](#ags312300-bib-0039){ref-type="ref"} of which majority of anastomosis site is not colorectal, were also included in our meta‐analysis. These results support our hypothesis that NSAIDs were associated with increased anastomotic leakage in all gastrointestinal anastomoses.

The present study had several limitations. First, our conclusions were mainly based on observational studies; however, subgroup analysis showed no significant subgroup difference between RCT and observational studies, suggesting that this potential bias was not significant. Second, there was statistical heterogeneity, and the included observational studies were clinically heterogenous in terms of patient characteristics, indications for surgery, and location of anastomoses. Although stratified and meta‐regression analyses showed no significant differences, heterogeneity decreased the validity of the results. Third, most of the included studies (17/24) only considered colorectal anastomoses, and the implication of the results for all gastrointestinal anastomoses might not be completely accurate.

In conclusion, postoperative NSAID use appears to be associated with an increased incidence of anastomotic leakage following gastrointestinal surgery. Selective COX‐2 inhibitors might be safer than non‐selective NSAIDs, although the results were inconclusive. Caution is warranted when using NSAIDs for postoperative analgesic control in patients with gastrointestinal anastomoses.

DISCLOSURE {#ags312300-sec-0021}
==========

Conflicts of Interest: Authors declare no conflicts of interest for this article.

Supporting information
======================

###### 

 

###### 

Click here for additional data file.

We thank Susan Furness, PhD, from Edanz Group (<http://www.edanzediting.com/ac>) for editing a draft of this manuscript.
